From June 14-15, 2022, the Process Pressure held a workshop to discover new approaches to imposing antitrust legal guidelines within the pharmaceutical business, gathering panelists from academia, authorities and coverage establishments.1 Whereas the proposals and arguments made by panelists don’t themselves represent the adoption of a brand new enforcement strategy by the businesses, they recommend that important adjustments could also be on the horizon.
FTC Chair Lina Khan set the stage for the workshop by noting the “troubling” state of affairs within the pharmaceutical business, observing specifically a historical past of great value will increase (20% per 12 months during the last 10+ years), the prevalence of so-called “killer acquisitions” (acquisitions which can be made for the aim of shutting down potential or nascent rivals), minimal innovation by main drug firms, and lawsuits towards those self same firms alleging unlawful bundling and tying.
Comments
0 comments